Management of Low Serum IgG

Diagnostic Workup

• Confirm persistent IgG deficiency – repeat quantitative IgG measurement at least one month apart to rule out transient decline or laboratory error. (Praxis Medical Insights) 1
• Screen for secondary protein loss – obtain serum total protein and albumin; concurrent low values suggest secondary hypogammaglobulinemia from protein‑losing states rather than a primary immunodeficiency. (American Academy of Allergy, Asthma & Immunology) 2
• Assess functional antibody responses – measure specific IgG responses to protein antigens (tetanus and diphtheria toxoids) to evaluate T‑cell‑dependent immunity. (Praxis Medical Insights) 3
• Evaluate polysaccharide vaccine response – administer the 23‑valent pneumococcal polysaccharide vaccine and measure serotype‑specific IgG concentrations 4 weeks later; poor responses indicate impaired T‑independent immunity. (American Academy of Allergy, Asthma & Immunology) 4
• Define severe impairment – for patients > 6 years, protective levels (>1.3 mg/mL) for ≤ 2 serotypes; for patients < 6 years, protective levels for < 50 % of serotypes. (American Academy of Allergy, Asthma & Immunology) 2
• Comprehensive immunoglobulin panel – quantify IgA, IgM, and all four IgG subclasses. (American Academy of Allergy, Asthma & Immunology) 4
• B‑cell phenotyping – flow cytometric enumeration of total B cells, CD27⁺ memory B cells, and class‑switched memory B cells. (Praxis Medical Insights) 3
• Lymphocyte subset analysis – count CD4⁺ and CD8⁺ T‑cells to exclude combined immunodeficiency. (American Academy of Allergy, Asthma & Immunology) 5
• Identify secondary causes – review use of immunosuppressive drugs (e.g., antiepileptics, gold salts, penicillamine, hydroxychloroquine, NSAIDs) and screen for HIV infection and occult malignancy (especially lymphoma). (American Academy of Allergy, Asthma & Immunology) 6

Differential Diagnosis Based on Laboratory Pattern

• Low IgG with normal IgA/IgM and normal vaccine responses – consider secondary hypogammaglobulinemia, unspecified hypogammaglobulinemia, or transient hypogammaglobulinemia of infancy. (American Academy of Allergy, Asthma & Immunology) 2
• Low IgG with normal IgA/IgM and impaired vaccine responses – suggest specific antibody deficiency or evolving common variable immunodeficiency (CVID). (American Academy of Allergy, Asthma & Immunology) 2
• Low IgG with low IgA ± IgM, low IgG subclasses, and impaired vaccine responses – consistent with CVID or transient hypogammaglobulinemia. (American Academy of Allergy, Asthma & Immunology) 2
• Low IgG with low IgA and normal/elevated IgM – indicative of hyper‑IgM syndrome (class‑switch defect). (American Academy of Allergy, Asthma & Immunology) 5
• Absent or markedly low all immunoglobulins – points to X‑linked agammaglobulinemia (XLA) or severe CVID; absent B cells on flow cytometry favor XLA. (American Academy of Allergy, Asthma & Immunology) 2

Management Algorithm

Patients Without Recurrent Infections

• Observation only – asymptomatic individuals with no history of recurrent sinopulmonary infections require no immediate therapy; schedule IgG monitoring every 6–12 months. (Praxis Medical Insights; American Academy of Allergy, Asthma & Immunology) [1][4]

Patients With Recurrent Infections

1. Aggressive Antimicrobial Therapy

• Prolonged antibiotic courses for acute infections, as standard durations may be insufficient in immunocompromised hosts. (American Academy of Allergy, Asthma & Immunology) 7
• Prophylactic antibiotics for recurrent sinopulmonary disease (e.g., amoxicillin 500–1000 mg daily or BID, TMP‑SMX 160 mg daily or BID, azithromycin 500 mg weekly or 250 mg every other day). (American Academy of Allergy, Asthma & Immunology) 8

2. Treat Contributing Factors

• Optimize control of atopic disease (allergic rhinitis, asthma) because allergic inflammation predisposes to respiratory infections. (American Academy of Allergy, Asthma & Immunology) 9

3. Immunoglobulin Replacement Therapy (IgRT)

• Indications – (a) markedly impaired antibody production documented by poor vaccine responses; (b) recurrent infections despite optimal antibiotics and prophylaxis; (c) permanent organ damage (bronchiectasis, bronchiolitis obliterans); (d) intolerable antibiotic side‑effects. (American Academy of Allergy, Asthma & Immunology) [6][9]4
• Dosing – intravenous immunoglobulin (IVIG) 400–600 mg/kg every 3–4 weeks; target trough IgG > 500 mg/dL for agammaglobulinemia or baseline + 300 mg/dL for CVID. (American Academy of Allergy, Asthma & Immunology) 4

Monitoring During IgRT

• IgG trough levels – obtain pre‑infusion (IVIG) or steady‑state (SCIG) measurements every 6–12 months. (American Academy of Allergy, Asthma & Immunology) 10
• Complete blood count – monitor for autoimmune cytopenias at the same interval. (American Academy of Allergy, Asthma & Immunology) 10
• Serum chemistry – liver enzymes, creatinine, and BUN every 6–12 months; more frequent (every 3–6 months) in growing children. (American Academy of Allergy, Asthma & Immunology) 7
• Dose adjustments – based on infection frequency, growth, weight change, or increased metabolic demand. (American Academy of Allergy, Asthma & Immunology) 7

Special Considerations

• IgA deficiency – does not contraindicate IgRT; anaphylaxis to IVIG in IgA‑deficient patients is exceedingly rare, and those who react may tolerate subcutaneous IgG. (American Academy of Allergy, Asthma & Immunology) 10
• Transient hypogammaglobulinemia of infancy – a trial of IgRT for 3–6 months may be justified when infections markedly impair quality of life and antibiotics fail; reassess immune function after discontinuation, and monitor rising IgA/IgM as markers of recovery. (American Academy of Allergy, Asthma & Immunology) [5][11]
• Venous access – avoid permanent central venous catheters solely for IVIG due to infection risk; consider subcutaneous IgG for patients with difficult venous access. (American Academy of Allergy, Asthma & Immunology) 7

Critical Pitfalls

• Do not diagnose immunodeficiency on a single low IgG value – confirm with repeat testing and functional antibody assessment. (Praxis Medical Insights) 1
• Do not initiate IgRT based only on laboratory abnormalities – require documented clinical disease (recurrent infections or organ damage). (Praxis Medical Insights) 12
• Always search for secondary causes (medications, protein‑losing conditions) before labeling primary immunodeficiency. (American Academy of Allergy, Asthma & Immunology) 6
• Avoid therapeutic delays once a definitive diagnosis is made, as postponement can lead to irreversible organ damage or fatal infection. (American Academy of Allergy, Asthma & Immunology) 9

Evaluation and Management of Low Serum IgG

Immunoglobulin Panel Testing

• Perform a comprehensive immunoglobulin panel that includes quantitative IgA, IgM, and all four IgG subclasses (IgG1‑4) to characterize the pattern of deficiency. 13

Functional Antibody Testing – Protein Antigens (T‑cell‑dependent)

• Measure specific IgG antibodies to tetanus and diphtheria toxoids to assess T‑cell‑dependent immunity; these responses are generally preserved except in severe pan‑hypogammaglobulinemia. 14

Functional Antibody Testing – Polysaccharide Antigens (T‑cell‑independent)

• Obtain baseline pneumococcal serotype‑specific IgG concentrations against the 23‑valent polysaccharide vaccine serotypes before any vaccination. 13
• If baseline levels are low or the patient has recurrent infections, administer the 23‑valent pneumococcal polysaccharide vaccine. 13
• Re‑measure serotype‑specific IgG concentrations 4–8 weeks after vaccination to evaluate B‑cell function. 13
• Define an impaired response as failure to achieve protective antibody levels (> 1.3 mg/mL) to more than 70 % of the tested serotypes in adults and children ≥ 6 years of age. 13

Interpretation of Pneumococcal Antibody Assays

• Recognize that pneumococcal antibody assays show considerable inter‑laboratory variability and quantify antibody amount rather than functional killing capacity; results must be interpreted in the clinical context of documented pneumococcal disease. 15
• Do not rely solely on pneumococcal antibody responses for diagnosis; correlate assay findings with clinical history of pneumococcal infection. 15

General Laboratory Evaluation

• Perform a complete blood count with differential to identify lymphopenia, neutropenia, lymphocytosis, or eosinophilia that may suggest primary immunodeficiency or other hematologic disorders. 13
• Conduct serum protein electrophoresis with immunofixation to detect monoclonal proteins and immune paresis associated with lymphoproliferative diseases (e.g., multiple myeloma, chronic lymphocytic leukemia, MGUS). 13

Clinical Decision‑Making and Treatment Thresholds

• Functional antibody testing is the cornerstone of determining clinical significance; quantitative IgG values alone cannot establish the need for therapy. 15
• Immunoglobulin replacement therapy should not be initiated based solely on laboratory abnormalities; it requires documented recurrent infections causing morbidity or established organ damage such as bronchiectasis. 15
• Isolated IgG subclass deficiencies without accompanying functional antibody defects rarely warrant treatment. 15